Congenital mitral valve insufficiency

Summary

Congenital mitral valve insufficiency (MONDO:0001298) is a disease and 3 clinical trials. Top therapeutic interventions include captopril, metoprolol, and torsemide. A subtype of vascular insufficiency disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	congenital mitral valve insufficiency
Mondo ID	MONDO:0001298
ICD-10-CM	Q23.3
ICD-11	403917903
NCIT	C197881
SNOMED CT	29928006
UMLS	C0158619
MedGen	510600
Anatomy (UBERON)	UBERON:0002135
Is cancer (heuristic)	no

Also known as: congenital insufficiency of mitral valve · congenital mitral insufficiency

Disease family

This is a subtype of vascular insufficiency disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vascular insufficiency disorder › congenital mitral valve insufficiency

Related subtypes (8): venous insufficiency, vertebrobasilar insufficiency, vertebral artery insufficiency, basilar artery insufficiency, tricuspid valve insufficiency, chronic intestinal vascular insufficiency, aortic valve insufficiency, splenic infarction

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06037434	Not specified	UNKNOWN	Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
NCT06037447	Not specified	UNKNOWN	Study of Innovative Strategies for Mitral Valve Repair
NCT06039592	Not specified	UNKNOWN	Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CAPTOPRIL	4	2
METOPROLOL	4	2
TORSEMIDE	4	2